Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BNGO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNGOBionano Genomics$3.38-0.7%$3.66$2.68▼$41.33$11.34M2.2110,805 shs52,291 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNGOBionano Genomics0.00%+2.58%-8.29%+11.39%-90.15%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBNGOBionano Genomics1.3213 of 5 stars3.13.00.00.00.00.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNGOBionano Genomics 2.25Hold$7.00107.41% UpsideCurrent Analyst Ratings BreakdownLatest BNGO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/9/2025BNGOBionano GenomicsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.00(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNGOBionano Genomics$30.78M0.37N/AN/A$18.12 per share0.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNGOBionano Genomics-$112.02M-$138.92N/A∞N/A-294.05%-125.75%-71.96%8/6/2025 (Estimated)Latest BNGO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025BNGOBionano Genomics-$3.49-$1.15+$2.34-$1.15$6.25 million$6.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBNGOBionano GenomicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNGOBionano Genomics0.071.701.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNGOBionano Genomics11.35%Insider OwnershipCompanyInsider OwnershipBNGOBionano Genomics0.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNGOBionano Genomics3003.36 million3.33 millionOptionableBNGO HeadlinesRecent News About These CompaniesBionano Genomics Inc News (BNGO) - Investing.comJune 25, 2025 | investing.comMaxim Group Upgrades Bionano Genomics (BNGO)May 20, 2025 | msn.comBionano Laboratories Announces a Second Category I CPT Code for OGM Established by the AMA; this one for Use in Whole Genome Analysis for Constitutional Genetic DisordersMay 19, 2025 | globenewswire.comBionano Genomics: Bionano Reports First Quarter 2025 Results and Highlights Recent Business ProgressMay 15, 2025 | finanznachrichten.deBionano Genomics stock rises on Q1 revenue beatMay 15, 2025 | msn.comBionano Genomics, Inc. (BNGO) Q1 2025 Earnings Call TranscriptMay 14, 2025 | seekingalpha.comBionano Reports First Quarter 2025 Results and Highlights Recent Business ProgressMay 14, 2025 | globenewswire.comA Glimpse of Bionano Genomics's Earnings PotentialMay 13, 2025 | benzinga.comBionano Genomics Q1 Earnings PreviewMay 13, 2025 | msn.comBionano Laboratories Announces Publication of the Largest Study To-Date Evaluating Clinical Utility of Optical Genome Mapping Across Multiple Hematologic MalignanciesMay 13, 2025 | globenewswire.comBionano to Report First Quarter 2025 Financial Results and Host a Conference Call Webcast on May 14, 2025May 7, 2025 | globenewswire.comInternational Consortium for Optical Genome Mapping Publishes Expert Recommendations for Integration of OGM as a Standard-of-Care Cytogenetic Assay for Diagnostic Workflows in Blood CancersMay 2, 2025 | globenewswire.comBionano Genomics announces publication on OGMApril 23, 2025 | markets.businessinsider.comBionano Announces Publication Showing OGM can Provide an Accurate and Cost-Effective Solution for Sizing Large Repeat Expansions in Constitutional Genetic DiseaseApril 23, 2025 | globenewswire.comBionano Genomics initiated with a Buy at H.C. WainwrightApril 9, 2025 | markets.businessinsider.comHC Wainwright & Co. Initiates Coverage of Bionano Genomics (BNGO) with Buy RecommendationApril 9, 2025 | msn.comBionano announces French publication of method for analysis of MM by OGMApril 8, 2025 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: CVS Health (CVS) and BioNano Genomics (BNGO)April 8, 2025 | markets.businessinsider.comBionano Announces French Publication of an Effective Method for Analysis of Multiple Myeloma by OGMApril 8, 2025 | manilatimes.netMBionano Announces French Publication of an Effective Method for Analysis of Multiple Myeloma by OGMApril 8, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBNGO Company DescriptionsBionano Genomics NASDAQ:BNGO$3.38 -0.03 (-0.74%) Closing price 07/3/2025 03:55 PM EasternExtended Trading$3.38 +0.00 (+0.15%) As of 07/3/2025 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA. The company also provides Saphyr and Bionano compute servers; and VIA software, which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; OGM-Dx HemeOne testing; OGM-Dx FSHD, a test for individuals suspected of having FSHD type 1; and OGM-Dx Postnatal Whole Genome SV and OGM-Dx Prenatal Whole Genome SV for comprehensive testing. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.